DE1003781T1 - Interleukin-18 bindende proteine, deren herstellung und verwendung - Google Patents

Interleukin-18 bindende proteine, deren herstellung und verwendung

Info

Publication number
DE1003781T1
DE1003781T1 DE1003781T DE98938877T DE1003781T1 DE 1003781 T1 DE1003781 T1 DE 1003781T1 DE 1003781 T DE1003781 T DE 1003781T DE 98938877 T DE98938877 T DE 98938877T DE 1003781 T1 DE1003781 T1 DE 1003781T1
Authority
DE
Germany
Prior art keywords
dna
antibody
protein
seq
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DE1003781T
Other languages
German (de)
English (en)
Inventor
Charles Dinarello
Hyun Kim
Daniela Novick
Menachem Rubinstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Original Assignee
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IL12155497A external-priority patent/IL121554A0/xx
Priority claimed from IL12163997A external-priority patent/IL121639A0/xx
Application filed by Yeda Research and Development Co Ltd filed Critical Yeda Research and Development Co Ltd
Publication of DE1003781T1 publication Critical patent/DE1003781T1/de
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/826—Viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/834—Urine; urinary system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
DE1003781T 1997-08-14 1998-08-13 Interleukin-18 bindende proteine, deren herstellung und verwendung Pending DE1003781T1 (de)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
IL12155497A IL121554A0 (en) 1997-08-14 1997-08-14 Interleukin-18 binding proteins their preparation and use
IL12163997A IL121639A0 (en) 1997-08-14 1997-08-27 Interleukin-18 binding proteins their preparation and use
IL12186097A IL121860A0 (en) 1997-08-14 1997-09-29 Interleukin-18 binding proteins their preparation and use
IL12213497A IL122134A0 (en) 1997-08-14 1997-11-06 Interleukin-18 binding proteins their preparation and use
IL12546398A IL125463A0 (en) 1997-08-14 1998-07-22 Interleukin-18 binding proteins their preparation and use
PCT/IL1998/000379 WO1999009063A1 (en) 1997-08-14 1998-08-13 Interleukin-18 binding proteins, their preparation and use

Publications (1)

Publication Number Publication Date
DE1003781T1 true DE1003781T1 (de) 2001-01-11

Family

ID=27517687

Family Applications (2)

Application Number Title Priority Date Filing Date
DE1003781T Pending DE1003781T1 (de) 1997-08-14 1998-08-13 Interleukin-18 bindende proteine, deren herstellung und verwendung
DE69841175T Expired - Lifetime DE69841175D1 (de) 1997-08-14 1998-08-13 Interleukin-18 bindende proteine, deren herstellung und verwendung

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69841175T Expired - Lifetime DE69841175D1 (de) 1997-08-14 1998-08-13 Interleukin-18 bindende proteine, deren herstellung und verwendung

Country Status (28)

Country Link
US (4) US6605280B1 (enExample)
EP (1) EP1003781B1 (enExample)
JP (1) JP4272348B2 (enExample)
KR (1) KR100687388B1 (enExample)
CN (1) CN1243021C (enExample)
AR (2) AR013422A1 (enExample)
AT (1) ATE443719T1 (enExample)
AU (1) AU755794B2 (enExample)
BG (1) BG65519B1 (enExample)
BR (1) BRPI9811940B8 (enExample)
CA (1) CA2298855C (enExample)
CY (1) CY1109664T1 (enExample)
CZ (1) CZ300818B6 (enExample)
DE (2) DE1003781T1 (enExample)
DK (1) DK1003781T3 (enExample)
EA (1) EA003675B1 (enExample)
EE (1) EE05538B1 (enExample)
ES (1) ES2149149T3 (enExample)
HU (1) HU226698B1 (enExample)
IL (5) IL121860A0 (enExample)
NO (1) NO327240B1 (enExample)
NZ (1) NZ502392A (enExample)
PL (1) PL206070B1 (enExample)
PT (1) PT1003781E (enExample)
SI (1) SI1003781T1 (enExample)
SK (1) SK287194B6 (enExample)
UA (1) UA75862C2 (enExample)
WO (1) WO1999009063A1 (enExample)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7393663B2 (en) * 1997-08-01 2008-07-01 Serono Genetics Institute S.A. Expressed sequence tags and encoded human proteins
IL121860A0 (en) * 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
CA2276216A1 (en) * 1998-06-24 1999-12-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo An artificial peptide capable of neutralizing the biological activity of interleukin-18
KR100537558B1 (ko) * 1998-09-01 2005-12-19 가부시끼가이샤 하야시바라 세이부쓰 가가꾸 겐꾸조 인터류킨-18 결합 단백질
AR022952A1 (es) 1999-03-19 2002-09-04 Smithkline Beecham Corp ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL
IL131047A0 (en) * 1999-07-22 2001-01-28 Yeda Res & Dev Use of il-18 inhibitors
DE60041432D1 (de) * 1999-11-16 2009-03-12 Hayashibara Biochem Lab Antikörper spezifisch für den Interleukin-18 Vorläufer
EP1257585A2 (en) * 2000-02-10 2002-11-20 Basf Aktiengesellschaft Antibodies that bind human interleukin-18 and methods of making and using
TR200502508T2 (tr) * 2000-02-21 2007-04-24 Applied Research Systems Ar� Holding N.V. IL-18 İnhibitörlerinin kullanımı.
AU2005211606B2 (en) * 2000-05-05 2007-02-22 Inserm - Institut National De La Sante Et De La Recherche Medicale Use of IL-18 inhibitors for the treatment and/or prevention of atherosclerosis
MXPA02010895A (es) * 2000-05-05 2003-03-27 Applied Research Systems Uso de inhibidores de interleucina 18 para el tratamiento y/o prevencion de aterosclerosis.
CA2424983A1 (en) 2000-10-11 2002-04-18 Viron Therapeutics, Inc. Nucleic acid molecules and polypeptides for immune modulation
US7718368B2 (en) * 2000-12-04 2010-05-18 Viron Therapeutics Inc. Immunomodulatory protein and useful embodiments thereof
KR100857376B1 (ko) * 2001-01-29 2008-09-05 라보라토리스 세로노 에스.에이. 심장 질환의 치료 및/또는 예방에 사용되는 ｉｌ-18저해물질
UA85531C2 (uk) * 2001-05-16 2009-02-10 Йеда Рисерч Энд Дивелопмент Ко. Лтд. Застосування il-18 інгібіторів для лікування або попередження пов'язаної з сепсисом дисфункції серця
HRP20030842B1 (hr) * 2001-05-25 2017-06-02 Ares Trading S.A. UPOTREBA IL-18 INHIBITORA ZA LIJEČENJE I PREVENCIJU OZLJEDA CNS-a
TR201809008T4 (tr) 2001-06-26 2018-07-23 Amgen Fremont Inc Opgl ye karşi antikorlar.
UA78516C2 (en) * 2001-08-10 2007-04-10 Applied Research Systems Use of inhibitors of il-18 for treatment and/or prevention of hypersensitivity disorders, and in particular of delayed-type hypersensitivity
JP4885424B2 (ja) * 2002-03-22 2012-02-29 メルク セロノ ソシエテ アノニム 末梢脈管疾患の治療および／または予防のためのｉｌ−１８阻害剤の使用
US20040136992A1 (en) 2002-08-28 2004-07-15 Burton Paul B. J. Compositions and method for treating cardiovascular disease
AU2003299919B2 (en) * 2002-10-08 2009-08-06 Ares Trading S.A. The use of cytokine able to bind IL-18BP and of inhibiting the activity of a second cytokine
IL152232A0 (en) * 2002-10-10 2003-05-29 Yeda Res & Dev Promoter to il-18bp, its preparation and use
WO2004097019A1 (ja) 2003-04-30 2004-11-11 Japan Science And Technology Agency ヒト抗ヒトインターロイキン－１８抗体およびその断片、並びにそれらの利用方法
ATE549353T1 (de) * 2003-05-13 2012-03-15 Merck Serono Sa Aktive varianten des il-18 bindenden proteins und dessen medizinische verwendungen
SI1689777T1 (sl) 2003-11-05 2007-08-31 Ares Trading Sa Postopek za äśiĺ äśenje il-18 vezavnega proteina
US20050100965A1 (en) 2003-11-12 2005-05-12 Tariq Ghayur IL-18 binding proteins
US7968684B2 (en) * 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
MXPA06005219A (es) * 2003-11-12 2007-01-19 Univ Colorado Regents Composiciones y metodos para la regulacion del factor-alfa de necrosis tumoral.
IL159670A0 (en) * 2003-12-31 2004-06-01 Yeda Res & Dev Use of il-18 binding protein in inflammations
ES2292127T3 (es) * 2004-03-01 2008-03-01 Ares Trading S.A. Uso de un medio de cultivo celular exento de suero para la produccion de il-18bp en celulas de mamiferos.
US7557084B2 (en) * 2004-03-31 2009-07-07 Regeneron Pharmaceuticals, Inc. IL-18 specific polypeptides and therapeutic uses thereof
EP1761552B1 (en) 2004-06-29 2008-09-17 Ares Trading S.A. Process for the purification of il-18 binding protein
EP1885753B1 (en) 2005-06-03 2011-07-27 Ares Trading S.A. Production of recombinant Il-18 binding protein
AU2006254106B2 (en) * 2005-06-03 2012-04-26 Merck Serono Sa Use of IL-18BP isoforms for the treatment and/or prevention of neurological inflammatory diseases
PT1891088E (pt) * 2005-06-10 2011-12-19 Ares Trading Sa Processo para a purificação da proteína de ligação il-18
CN101003812B (zh) * 2006-01-17 2011-01-05 温州医学院 一种用于制备重组人egf-il18融合蛋白的方法
EP2027157B1 (en) 2006-05-25 2014-08-06 Glaxo Group Limited Modified humanised anti-interleukin-18 antibodies
WO2010040736A2 (en) * 2008-10-07 2010-04-15 Ablynx Nv Amino acid sequences directed against il18 and/or the il-18 receptor and polypeptides comprising the same for the treatment of diseases and/or disorders associated with il-18 mediated signaling
US20150352561A1 (en) * 2013-01-02 2015-12-10 Wilsa Holdings ,LLC Method and Apparatus for Conditioning Fluids
NZ717671A (en) * 2013-09-05 2022-07-01 Ab2 Bio Sa Il-18 binding protein (il-18bp) in inflammatory diseases
MX2017010919A (es) 2015-03-05 2017-12-07 Ab2 Bio Sa Proteina de union il-18 (il-18bp) y anticuerpos en enfermedades inflamatorias.
EP3943097A1 (en) 2020-07-24 2022-01-26 AB2 Bio SA Car-t cell therapy
WO2023143535A1 (zh) * 2022-01-28 2023-08-03 和径医药科技（上海）有限公司 一种靶向il-18bp的抗体及其应用
WO2023178192A1 (en) * 2022-03-15 2023-09-21 Compugen Ltd. Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer
CN114605521A (zh) * 2022-04-06 2022-06-10 内蒙古农业大学 一种细胞免疫调节蛋白及其应用
CN114891125B (zh) * 2022-06-16 2023-04-11 广东医科大学 一种长效重组白细胞介素-18结合蛋白及其生产方法与应用
KR20250133728A (ko) 2023-01-06 2025-09-08 라센 테라퓨틱스, 인코포레이티드 항-il-18bp 항체
TW202515608A (zh) 2023-06-26 2025-04-16 以色列商坎布根有限公司 Ｉｌ—１８ｂｐ拮抗抗體及其於癌症治療之單一療法及組合療法的用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985863A (en) 1996-09-12 1999-11-16 Vertex Pharmaceuticals, Inc. Compositions and methods for decreasing IGIF and IFN-γ production by administering an ICE inhibitor
GB9214857D0 (en) * 1992-07-13 1992-08-26 Medical Res Council Human nucleic acid fragments and their use
US5744451A (en) 1995-09-12 1998-04-28 Warner-Lambert Company N-substituted glutamic acid derivatives with interleukin-1 β converting enzyme inhibitory activity
US5776731A (en) 1996-02-21 1998-07-07 Immunex Corporation DNA encoding type-I interleukin-I receptor-like protein designated 2F1
ES2213209T3 (es) 1996-11-15 2004-08-16 Kennedy Institute Of Rheumatology Supresion de tnfalfa e il-12 en terapia.
CA2274250A1 (en) 1996-12-06 1998-06-11 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1.beta. converting enzyme
US7141393B2 (en) 1996-12-26 2006-11-28 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18-receptor proteins
US6087116A (en) 1997-03-12 2000-07-11 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18 (IL-18) receptor polypeptides and their uses
HUP0104439A3 (en) 1997-03-18 2002-08-28 Basf Ag Pharmaceutical compositions for modulating responsiveness to corticosteroids and use thereof
DK1000151T3 (da) 1997-08-01 2006-10-02 Serono Genetics Inst Sa 5'EST'er for secernerede proteiner udtrykt i forskellige væv
JP2001512012A (ja) 1997-08-01 2001-08-21 ジェンセット 精巣およびその他の組織で発現する分泌タンパク質の５’ｅｓｔ
IL121860A0 (en) * 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
PL193352B1 (pl) 1998-04-28 2007-02-28 Applied Research Systems Koniugat poliol-interferon ß, sposób jego wytwarzania i jego zastosowanie oraz kompozycja farmaceutyczna
CA2276216A1 (en) 1998-06-24 1999-12-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo An artificial peptide capable of neutralizing the biological activity of interleukin-18
KR100537558B1 (ko) 1998-09-01 2005-12-19 가부시끼가이샤 하야시바라 세이부쓰 가가꾸 겐꾸조 인터류킨-18 결합 단백질
AR022952A1 (es) 1999-03-19 2002-09-04 Smithkline Beecham Corp ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL
WO2001003719A2 (en) 1999-07-09 2001-01-18 Amgen Inc. Combination therapy for conditions leading to bone loss
WO2001019373A2 (en) 1999-09-17 2001-03-22 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids

Also Published As

Publication number Publication date
EP1003781B1 (en) 2009-09-23
CN1243021C (zh) 2006-02-22
WO1999009063A1 (en) 1999-02-25
SK1762000A3 (en) 2000-09-12
NO20000700L (no) 2000-04-14
PL338647A1 (en) 2000-11-06
KR100687388B1 (ko) 2007-02-26
CN1267307A (zh) 2000-09-20
AU755794B2 (en) 2002-12-19
IL134523A0 (en) 2001-04-30
BG104149A (bg) 2000-08-31
US20060154294A1 (en) 2006-07-13
US7101689B2 (en) 2006-09-05
AU8746098A (en) 1999-03-08
HUP0003533A2 (hu) 2001-01-29
ES2149149T1 (es) 2000-11-01
CY1109664T1 (el) 2014-08-13
EA200000216A1 (ru) 2000-08-28
EE200000073A (enExample) 2000-10-16
ATE443719T1 (de) 2009-10-15
JP2001514876A (ja) 2001-09-18
BRPI9811940A (pt) 2000-09-05
US20100010200A1 (en) 2010-01-14
KR20010022900A (ko) 2001-03-26
HU226698B1 (en) 2009-07-28
NO20000700D0 (no) 2000-02-11
AR013422A1 (es) 2000-12-27
IL134523A (en) 2011-09-27
EE05538B1 (et) 2012-04-16
NZ502392A (en) 2002-12-20
HUP0003533A3 (en) 2003-08-28
CA2298855A1 (en) 1999-02-25
CZ2000490A3 (cs) 2000-08-16
AR062867A2 (es) 2008-12-10
DE69841175D1 (de) 2009-11-05
EA003675B1 (ru) 2003-08-28
PT1003781E (pt) 2009-10-26
SI1003781T1 (sl) 2009-12-31
NO327240B1 (no) 2009-05-18
SK287194B6 (sk) 2010-03-08
US20040037829A1 (en) 2004-02-26
JP4272348B2 (ja) 2009-06-03
US8436148B2 (en) 2013-05-07
ES2149149T3 (es) 2009-12-01
CZ300818B6 (cs) 2009-08-19
IL121860A0 (en) 1998-02-22
IL122134A0 (en) 1998-04-05
BRPI9811940B8 (pt) 2021-07-06
US7799541B2 (en) 2010-09-21
CA2298855C (en) 2014-05-27
US6605280B1 (en) 2003-08-12
HK1028773A1 (en) 2001-03-02
BRPI9811940B1 (pt) 2011-10-04
PL206070B1 (pl) 2010-06-30
IL125463A0 (en) 1999-03-12
EP1003781A1 (en) 2000-05-31
DK1003781T3 (da) 2010-01-25
UA75862C2 (uk) 2006-06-15
BG65519B1 (bg) 2008-10-31

Similar Documents

Publication Publication Date Title
DE1003781T1 (de) Interleukin-18 bindende proteine, deren herstellung und verwendung
DE69434053T2 (de) Verkürzter keratinocytenwachstumsfaktor(kgf)mit erhöhter biologischer aktivität
DE69028671T3 (de) Löslisches extrazellulares Fragment des menschlischen IFN-beta 2/IL-6-Rezeptors, seine Herstellung und diesen Fragment enthaltende pharmazeutische Mischung
DE69824755T2 (de) Cytokinähnliches polypeptid-10 aus säugetieren
DE69630710T2 (de) Humaner tumornekrosefaktor delta und epsilon
DE69017753T3 (de) Tumor-Nekrosefaktor-Bindungsprotein II, seine Reinigung und spezifische Antikörper
DE69824719T2 (de) Cytokinähnlicher faktor-7 aus säugetieren
DE69531892T2 (de) Fibroblasten-wachstumsfaktor 10
DE68929387T2 (de) Interleukin-1-Inhibitoren
DE69505804T2 (de) Afamin: ein menschliches serum albumin ähnliches protein
DE69532436T2 (de) Einzelkettenformen des clycoprotein-hormon-quartetts
DE68908633T2 (de) Polypeptide mit zellenverstreuender Aktivität.
WO1995003328A2 (de) Melanom-inhibierendes protein
DE69926627T2 (de) Insulinartigen wachstumsfaktor bindendes protein -3 variante
EP0875567A2 (de) Myc-bindende Zinkfinger-Proteine, ihre Herstellung und ihre Verwendung
DE69132813T2 (de) Genetisches igfbp-5 rodierendes material
DE69522492T2 (de) Verfahren zur Herstellung von Alpha-Interferon
DE69732350T2 (de) Persephin und verwandte wachstumsfaktoren
Inoue et al. Neuron-specific antigen HPC-1 from bovine brain reveals strong homology to epimorphin, an essential factor involved in epithelial morphogenesis: identification of a novel protein family
DE69333063T2 (de) Vekürztes insulinähnlichen wachstumsfaktor-bindendes protein mit mitogener aktivität
DE69131979T2 (de) Genetisches igfbp-4 rodierendes material
DE3536939A1 (de) Biologisch aktive derivate des human-(gamma)-interferons, ihre herstellung und arzneimittel, die solche derivate enthalten
DE69233155T2 (de) Insulinartigen wachstumsfaktor bindendes protein
CA2128215C (en) Autotaxin: motility stimulating protein useful in cancer diagnosis and therapy
DE68923496T2 (de) Verfahren zur Herstellung von motilinähnlichen Polypeptiden und seine Expression.